Perlegen Introduces BREVAGen⢠Breast Cancer Risk Stratification Test

Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that its BREVAGenâ„¢ breast cancer risk stratification test is now clinically available in select U.S. markets. Perlegen plans to add sales areas to make the test available nationwide over the next few months.